Spyros Papapetropoulos

Dr. Spyros Papapetropoulos is a recognized researcher, an experienced biopharmaceutical executive and a digital health expert. He is currently EVP, Head of Research and Development and Chief Medical Officer (CMO) at Cavion, with a mission to "Restore the Brain's Natural Rhythms" by modulating overactive T-type calcium channels for a range of neurological and rare genetic diseases.

Prior that that, Spyros was the Vice President and Global Head of Neurodegeneration and Movement Disorders at TEVA Pharmaceuticals. Prior joining TEVA he held positions of increasing responsibility at Pfizer’s Neuroscience Research Unit, Allergan’s Global Medical Affairs and Biogen’s Experimental Neurology Unit. He has filed multiple INDs and overseen a wide spectrum of development programs leading to successful regulatory filings and new product launches. He has led in-licencing efforts and corporate partnerships with profit and non-profit organizations. Spyros has proven people skills, is a strong leader focused on innovation, organizational excellence and efficiency.

Spyros is a board-certified Neurologist and a Movement Disorders specialist trained at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. He received his PhD on medical genetics. He started his career in academic neurology. His primary academic interests remain in genomics and digital health. Spyros is currently co-chairing the newly formed International Parkinson’s Disease and Movement Disorders Society’s (IPMDS) Taskforce on Technology.

Spyros has authored over 150 peer-reviewed publications, 5 book chapters and presented in meetings since 1998.

He is a member of numerous foundations and associations and holds appointments as Consultant with Massachusetts General Hospital and Voluntary Associate Professor of Neurology with the University of Miami, Miller School of Medicine.